Lara Longpre
2022
In 2022, Lara Longpre earned a total compensation of $1.5M as Chief Development Officer at Mirum Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $216,000 |
|---|---|
| Option Awards | $670,596 |
| Salary | $450,000 |
| Stock Awards | $158,700 |
| Other | $12,200 |
| Total | $1,507,496 |
Longpre received $670.6K in option awards, accounting for 44% of the total pay in 2022.
Longpre also received $216K in non-equity incentive plan, $450K in salary, $158.7K in stock awards and $12.2K in other compensation.
Rankings
In 2022, Lara Longpre's compensation ranked 2,221st out of 5,756 executives tracked by ExecPay. In other words, Longpre earned more than 61.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,221 out of 5,756 | 61st |
Division Manufacturing | 1,202 out of 3,133 | 62nd |
Major group Chemicals And Allied Products | 525 out of 1,419 | 63rd |
Industry group Drugs | 483 out of 1,320 | 63rd |
Industry Pharmaceutical Preparations | 350 out of 966 | 64th |
Source: SEC filing on May 1, 2023.
Longpre's colleagues
We found three more compensation records of executives who worked with Lara Longpre at Mirum Pharmaceuticals in 2022.